InterMune Jumps After Dodging “Extremely Critical” FDA Review BusinessWeek March 5 (Bloomberg) -- InterMune Inc.'s experimental medicine for a deadly lung disease was reviewed more favorably by US regulators than analysts expected, sending the company's shares surging. InterMune almost doubled in early ... US FDA staff: Effect of InterMune lung drug unclear FDA To Review InterMune Drug Application Next Week; Shares Soar InterMune rallies ahead of FDA meeting |
Friday, March 5, 2010
InterMune Jumps After Dodging “Extremely Critical” FDA Review - BusinessWeek
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment